NEW YORK (WABC) -- Manuel Greco has Von Hippel-Lindau disease. It's a rare condition that causes tumors to grow in certain parts of the body. Most of the tumors are benign but they often grow back ...
HIF-2 alpha inhibitors are transforming therapy for patients with renal cell carcinoma and von Hippel-Lindau disease. Sean Korbitz had his first bout with cancer — a brain tumor discovered after six ...
When Sean Korbitz was a 20-year-old college student, his life trajectory changed with a rare cancer diagnosis, resulting in the removal of 40 tumors; fifteen years later, a new drug made him feel like ...
China’s National Medical Products Administration (NMPA) has approved MSD’s hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, oral WELIREG (belzutifan), to treat adults with certain types of von ...
GlobalData on MSN
EC conditionally approves MSD’s Welireg for VHL disease and RCC
The European Commission (EC) has conditionally approved MSD's Welireg, an oral hypoxia-inducible factor-2 alpha (HIF-2α) ...
The EC conditionally approved Merck’s Welireg for certain VHL disease-associated tumors and advanced RCC after two or more prior treatments. Approval is based on data from the LITESPARK-004 and ...
Moderate to advanced chronic kidney disease is an underappreciated burden of von Hippel-Lindau (VHL)-associated renal cell carcinoma (RCC) treated with surgery, which also includes frequent disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback